Evidences on the efficacy and the effectiveness of the first generation COVID-19 vaccines in the clinical trials and real-world studies

This version is not peer-reviewed
This is not the most recent version. There is anewer versionof this content available.

Jingxin Li* NHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, People's Republic of China.++School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.

Zhuopei Li School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.

Yawen Zhu School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.

Li Zhou School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.

Fengcai Zhu* NHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, People's Republic of China.++School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.


Abstract

More than 300 COVID-19 vaccine candidates have been developed or are still in development. COVID-19 vaccines in the World Health Organization Emergency Use Listing and some other COVID-19 vaccine products under conditional approval by national regulatory authorities are already in largescale use, preventing populations from severe illness or death and inducing herd immunity to impact the SARS-CoV-2 pandemic. In this review, we systemically assess the vaccine efficacy and effectiveness of COVID-19 vaccines in clinical trials or real-world studies, in various populations, including healthy adults, children, the elderly, pregnancy women, people with cancer, rheumatic and musculoskeletal diseases, chronic hemodialysis, solid organ transplantation, and so on. In addition, we reviewed the available effectiveness evidence on the immunization strategies of COVID-19 vaccines in those who have previous infection history of SARS-CoV-2, and the enhanced effectiveness associated with various boosting immunization. We also discuss the unmet gaps about the persistence and spectrum of vaccine protection provided by the current available COVID-19 vaccines.

Comments
Send
Doi
Keywords
Subject Area
Clinical Trials*, Epidemiology*
Now Published
Version History
  • 20 Sep 2022 10:37 Version 1
Scores
 4.24
Rapid Rating Times: 1.
Each rating ranges from 0-5.
Level of Quality: 4.
Level of Repeatability: 5.
Level of Innovation: 5.
Level of Impact: 3.
Rapid Rating
Your professional field is different from the direction of this article
Settings
  • Level of Quality
    Is the publication of relevance for the academic community and does it provide important insights? Is the language correct and easy to understand for an academic in the field? Are the figures well displayed and captions properly described? Is the article systematically and logically organized?
    0.0
  • Level of Repeatability
    Is the hypothesis clearly formulated? Is the argumentation stringent? Are the data sound, well-controlled and statistically significant? Is the interpretation balanced and supported by the data? Are appropriate and state-of-the-art methods used?
    0.0
  • Level of Innovation
    Does the work represent a novel approach or new findings in comparison with other publications in the field?
    0.0
  • Level of Impact
    Does the work have potential huge impact to the related research area?
    0.0
Submit

我们使用 cookie 将您与其他用户区分开来, 并在我们的网站上为您提供更好的体验。

关闭此消息以接受 cookie 或了解如何管理您的 cookie 设置。

了解更多关于我们的隐私声明..

goTop